NEW YORK (GenomeWeb) – Enzo Biochem today reported flat year-over-year revenues for its fiscal third quarter. 

For the three months ended April 30, the firm recorded total revenues of $24 million, the same as a year ago. Enzo Clinical Labs' revenues were up 8 percent to $15.7 million from $14.5 million, but Life Sciences revenues, which comprise Enzo's product revenues, slid 9 percent to $7.9 million from $8.7 million due to the effects of currency exchange and the timing of customer reordering patterns, Enzo said. Royalty and license fee income dropped to $423,000 from $729,000. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.